As of September 12, 2026, the three largest insider holders of QCLS are Paul Rivard (Chief Legal Officer, 400.00K shares), Joshua Silverman (Executive Chairman, 262.19K shares), Chelsea Sierra Voss (Director, 239.90K shares).
| # | Insider | Position | Direct | Indirect | Total | Share of Insiders | Last Filed |
|---|---|---|---|---|---|---|---|
| 1 | Joshua Silverman | Executive Chairman | 262,199 | 0 | 262,199 | 61.9% | 15 Apr, 2026 |
| 2 | Chelsea Sierra Voss | Director | 0 | 61,555 | 61,555 | 14.5% | 14 May, 2026 |
| 3 | Billy Joe White | Director | 25,024 | 0 | 25,024 | 5.9% | 17 Nov, 2025 |
| 4 | Bruce Bernstein | Director | 25,000 | 0 | 25,000 | 5.9% | 14 Nov, 2025 |
| 5 | Stephen Friscia | Director | 25,000 | 0 | 25,000 | 5.9% | 14 Nov, 2025 |
| 6 | Gary M Rauch | Other | 12,500 | 0 | 12,500 | 2.9% | 14 Nov, 2025 |
| 7 | Mitchell Glass | Director, Chief Medical Off. | 12,500 | 0 | 12,500 | 2.9% | 17 Nov, 2025 |
| 8 | Paul Rivard | Chief Legal Officer | 35 | 0 | 35 | 0.0% | 24 Aug, 2023 |
Each row is that insider’s most recently reported position, from Form 4 filings over the last 60 months — which is why this total does not tie to the quarterly series above, where a quarter counts only the insiders who filed in it. Shares held through a fund or institutional portfolio are counted on the institutional ownership page instead.
| Date | Insider | Position | Transaction | Shares | Price | Value | Shares Held After | Ownership |
|---|---|---|---|---|---|---|---|---|
| 30 Mar, 2026 | Chelsea Sierra Voss | Director | Acquired P | 1,753 | $3.15 | $5.52K | 61,555 | Indirect |
| 13 Apr, 2026 | Billy Joe White | Director | Acquired A | 50,000 | $0.00 | $0 | 50,000 | Direct |
| 13 Apr, 2026 | Joshua Silverman | Executive Chairman | Acquired A | 162,162 | $0.00 | $0 | 262,191 | Direct |
| 13 Apr, 2026 | Chelsea Sierra Voss | Director | Acquired A | 50,000 | $0.00 | $0 | 50,000 | Direct |
| 13 Apr, 2026 | Stephen Friscia | Director | Acquired A | 50,000 | $0.00 | $0 | 50,000 | Direct |
| 13 Apr, 2026 | Mitchell Glass | Chief Medical Officer | Acquired A | 50,000 | $0.00 | $0 | 50,000 | Direct |
| 13 Apr, 2026 | Bruce Bernstein | Director | Acquired A | 50,000 | $0.00 | $0 | 50,000 | Direct |
| 13 Apr, 2026 | Joshua Silverman | Executive Chairman | Acquired A | 100,000 | $0.00 | $0 | 50,000 | Direct |
| 16 Jan, 2026 | Chelsea Sierra Voss | Director | Acquired A | 212,500 | $0.00 | $0 | 214,900 | Direct |
| 16 Jan, 2026 | Chelsea Sierra Voss | Director | Acquired A | 25,000 | $0.00 | $0 | 239,900 | Direct |
| 16 Jan, 2026 | Chelsea Sierra Voss | Director | Acquired A | 212,500 | $0.00 | $0 | 212,500 | Direct |
| 04 Sep, 2025 | Biotech, Inc. Pharmacyte | TenPercentOwner | Acquired P | 889,865 | — | — | 889,865 | Direct |
| 14 Nov, 2025 | Biotech, Inc. Pharmacyte | TenPercentOwner | Acquired P | 889,865 | — | — | 889,865 | Direct |
| 14 Nov, 2025 | Mitchell Glass | Director, Chief Medical Off. | Acquired A | 11,420 | $0.00 | $0 | 12,500 | Direct |
| 14 Nov, 2025 | Billy Joe White | Director | Acquired A | 22,839 | $0.00 | $0 | 25,024 | Direct |
| 14 Nov, 2025 | Gary M Rauch | Other | Acquired A | 11,420 | $0.00 | $0 | 12,500 | Direct |
| 14 Nov, 2025 | Stephen Friscia | Director | Acquired A | 22,839 | $0.00 | $0 | 25,000 | Direct |
| 14 Nov, 2025 | Bruce Bernstein | Director | Acquired A | 25,000 | $0.00 | $0 | 25,000 | Direct |
| 14 Nov, 2025 | Joshua Silverman | Executive Chairman | Acquired A | 91,356 | $0.00 | $0 | 100,029 | Direct |
| 03 Oct, 2025 | Gary M Rauch | Other | Acquired A | 1,080 | $0.00 | $0 | 1,080 | Direct |